You are here

MICRODROPLET-BASED SUSTAINED DELIVERY OF AZIDOTHYMIDINE

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 18932
Amount: $49,810.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1992
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4364 South Alston Avenue
Durham, NC 27713
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Indu Parikh
 (919) 361-2277
Business Contact
Phone: () -
Research Institution
N/A
Abstract

THE FORMATION OF MICRODROPLET FORMULATIONS OF A DRUG, A MEANS OF IMPROVING TISSUE COMPATIBILITYAND OF PROVIDING SUSTAINED RELEASE, INVOLVES THE PREPARATION OF MICROSPHERES (O.1 MICRON DIAMETER) OF A DRUG-CONTAINING OIL PHASE, AND THEIR ENCAPSULATION WITH A LAYER OF PHOSPHOLIPID.A RAT MODEL WILL BE USED TO TEST THE MICRODROPLET TECHNOLOGY-BASED SUSTAINED DELIVERY OF AZIDOTHYMIDINE, WHICH IS INTENDED TO PROVIDE UP TO A ONE WEEK TREATMENT REGIMEN FOR HIV INFECTION. A SERIES OF MICRODROPLET FORMULATIONS CONTAINING DIFFERENT CONCENTRATIONS OF AZIDOTHYMIDINE WILL BE PREPARED IN AT LEAST THREE TISSUE-COMPATIBLE AND FDA-APPROVED SYNTHETIC OILS. THE DRUG RELEASE KINETICS OF THE AZT-CONTAINING MICRODROPLETS WILL BE TESTED IN AN IN VITRO MODEL AS WILL AS BY INTRADERMAL AND INTRAMUSCULAR INJECTIONS INTO RATS. A FORMULATION WHICH PROVIDES ACCEPTABLE (I.E. ZERO ORDER) RELEASE KINETICE OVER A PERIOD OF ONE WEEK WILL BE IDENTIFIED FOR FURTHER DEVELOPMENT IN PHASE II.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government